Newsroom | 23575 results
Sorted by: Latest
-
Mirum Pharmaceuticals gibt bekannt, dass der primäre Endpunkt in der Phase-3-Studie AZURE-1 zu Brelovitug bei chronischer Hepatitis-Delta-Virus-Infektion erreicht wurde
FOSTER CITY, Kalifornien--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), ein führendes Unternehmen im Bereich seltener Krankheiten, gab heute bekannt, dass der primäre Endpunkt im Phase-3-Teil der AZURE-1-Studie erreicht wurde, in der Brelovitug, ein in der Erprobung befindlicher, vollständig humaner monoklonaler Antikörper, der an das Hepatitis-B-Oberflächenantigen (HBsAg) bindet, zur Behandlung der chronischen Hepatitis-Delta-Virus-Infektion (HDV) untersucht wurde. Darüber hinau...
-
Resumen: Mirum Pharmaceuticals anuncia que se ha cumplido el criterio de valoración principal en el estudio de fase III AZURE-1 sobre brelovitug para tratar la hepatitis crónica por el virus delta
FOSTER CITY, California.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), una empresa líder en el ámbito de las enfermedades raras, ha anunciado hoy que se ha cumplido el criterio de valoración principal en la parte de fase III del estudio AZURE-1, que evalúa el brelovitug, un anticuerpo monoclonal totalmente humano en fase de investigación que se une al antígeno de superficie de la hepatitis B (HBsAg), para tratar la hepatitis crónica por el virus delta (HDV). El comunicado en el...
-
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
BOSTON & SHANGHAI--(BUSINESS WIRE)--Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)...
-
Samenvatting: Mirum Pharmaceuticals maakte bekend dat het primaire eindpunt is bereikt in de Fase 3 AZURE-1 studie van brelovitug bij chronische hepatitis delta-virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), een toonaangevend bedrijf gespecialiseerd in zeldzame aandoeningen, maakte vandaag bekend dat het primaire eindpunt is voldaan in het Fase 3-gedeelte van de AZURE-1 studie ter beoordeling van brelovitug, een volledig humaan monoklonaal antilichaam in onderzoeksfase dat zich bindt aan HBsAg (hepatitis B-surface-antigeen), voor de behandeling van chronische HDV (chronische hepatitis delta-virus). Deze bekendmaking i...
-
Riassunto: Mirum Pharmaceuticals annuncia che brelovitug ha raggiunto l'endpoint primario dello studio di Fase 3 AZURE-1 per il trattamento del virus dell'epatite cronica Delta
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), azienda leader nel settore delle malattie rare, oggi ha reso noto che l'endpoint primario è stato raggiunto nella parte di Fase 3 dello studio clinico AZURE-1 volto a valutare brelovitug, un anticorpo monoclonale sperimentale completamente umano che si lega all'antigene di superficie dell'epatite B (HBsAg), per il trattamento del virus dell'epatite cronica Delta (HDV). Il testo originale del presente annuncio, red...
-
Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS
TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, today announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase 2a clinical study evaluating Pegevongitide (AV-001) in patients hospitalized with pneumonia requiring supplemental oxygen. Pegevongitide has received Fast Track designation from the U.S...
-
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus...
-
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS)...
-
Contamination Protection Solution Highlights Covalon’s Presence at the Association for Vascular Access 2026 Annual Scientific Meeting
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation at the Association for Vascular Access (AVA) Annual Scientific Meeting in Grapevine, Texas, from October 2 to 4, 2026, with pre-meeting workshops on October 1. Attendees will have the opportunity to explore Covalon’s innovative vascular access and infection prevention solutions and learn why leading h...
-
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi....
